{"id":2658,"date":"2017-09-01T20:34:34","date_gmt":"2017-09-02T04:34:34","guid":{"rendered":"https:\/\/www.sfj-pharma.com\/?p=793"},"modified":"2021-05-13T14:34:22","modified_gmt":"2021-05-13T22:34:22","slug":"mylortarg-received-fda-approval","status":"publish","type":"post","link":"https:\/\/www.sfj-pharma.com\/mylortarg-received-fda-approval\/","title":{"rendered":"Mylortarg received FDA approval"},"content":{"rendered":"<h3>PFIZER RECEIVES FDA APPROVAL FOR MYLOTARG\u2122 (GEMTUZUMAB OZOGAMICIN)<\/h3>\n<p>ONLY APPROVED ANTIBODY-DRUG CONJUGATE FOR NEWLY DIAGNOSED AND RELAPSED OR REFRACTORY CD33-POSITIVE ACUTE MYELOID LEUKEMIA<\/p>\n<p>REINTRODUCTION OF MYLOTARG SUPPORTED BY CONTINUED RESEARCH BY THE AML COMMUNITY DEMONSTRATING FAVORABLE RISK:BENEFIT PROFILE<\/p>\n<p><strong>Friday, September 1, 2017 &#8211; 11:38am EDT<\/strong><br \/>\nPfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration approved MYLOTARG\u2122 (gemtuzumab ozogamicin) for adults with newly diagnosed CD33-positive acute myeloid leukemia (AML), and adults and children 2 years and older with relapsed or refractory CD33-positive AML.1 MYLOTARG is the first therapy with an indication that includes pediatric AML. It is also the only AML therapy that targets CD33, an antigen expressed on AML cells in up to 90% of patients.<\/p>\n<p>\u201cThe FDA approval of MYLOTARG fills a critical unmet need for many adults and children with AML, which can be fatal in a matter of months or even weeks if not treated and has a high relapse rate,\u201d said Liz Barrett, global president, Pfizer Oncology. \u201cBased on clinical data, real-world experience and support from the AML community, we are grateful MYLOTARG now has the potential to help a broad range of AML patients.\u201d<\/p>\n<h3><a href=\"https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer_receives_fda_approval_for_mylotarg_gemtuzumab_ozogamicin\" target=\"_blank\" rel=\"noopener noreferrer\">Read full press release<\/a><\/h3>\n","protected":false},"excerpt":{"rendered":"<p>PFIZER RECEIVES FDA APPROVAL FOR MYLOTARG\u2122 (GEMTUZUMAB OZOGAMICIN) ONLY APPROVED ANTIBODY-DRUG CONJUGATE FOR NEWLY DIAGNOSED AND RELAPSED OR REFRACTORY CD33-POSITIVE ACUTE MYELOID LEUKEMIA REINTRODUCTION OF MYLOTARG SUPPORTED BY CONTINUED RESEARCH BY THE AML COMMUNITY DEMONSTRATING FAVORABLE RISK:BENEFIT PROFILE Friday, September 1, 2017 &#8211; 11:38am EDT&#8230;<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[103],"tags":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.2 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Mylortarg received FDA approval - SFJ Pharmaceuticals<\/title>\n<meta name=\"description\" content=\"Pfizer Inc. announced that the U.S. Food and Drug Administration approved MYLOTARG\u2122 (gemtuzumab ozogamicin) for adults with newly diagnosed CD33-positive acute myeloid leukemia (AML), and adults and children 2 years and older\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.sfj-pharma.com\/mylortarg-received-fda-approval\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Mylortarg received FDA approval - SFJ Pharmaceuticals\" \/>\n<meta property=\"og:description\" content=\"Pfizer Inc. announced that the U.S. Food and Drug Administration approved MYLOTARG\u2122 (gemtuzumab ozogamicin) for adults with newly diagnosed CD33-positive acute myeloid leukemia (AML), and adults and children 2 years and older\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.sfj-pharma.com\/mylortarg-received-fda-approval\/\" \/>\n<meta property=\"og:site_name\" content=\"SFJ Pharmaceuticals\" \/>\n<meta property=\"article:published_time\" content=\"2017-09-02T04:34:34+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-05-13T22:34:22+00:00\" \/>\n<meta name=\"author\" content=\"khateam\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"khateam\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.sfj-pharma.com\/mylortarg-received-fda-approval\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.sfj-pharma.com\/mylortarg-received-fda-approval\/\"},\"author\":{\"name\":\"khateam\",\"@id\":\"https:\/\/www.sfj-pharma.com\/#\/schema\/person\/049145e1c21636813c9d02a662ef41cc\"},\"headline\":\"Mylortarg received FDA approval\",\"datePublished\":\"2017-09-02T04:34:34+00:00\",\"dateModified\":\"2021-05-13T22:34:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.sfj-pharma.com\/mylortarg-received-fda-approval\/\"},\"wordCount\":202,\"publisher\":{\"@id\":\"https:\/\/www.sfj-pharma.com\/#organization\"},\"articleSection\":[\"News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.sfj-pharma.com\/mylortarg-received-fda-approval\/\",\"url\":\"https:\/\/www.sfj-pharma.com\/mylortarg-received-fda-approval\/\",\"name\":\"Mylortarg received FDA approval - SFJ Pharmaceuticals\",\"isPartOf\":{\"@id\":\"https:\/\/www.sfj-pharma.com\/#website\"},\"datePublished\":\"2017-09-02T04:34:34+00:00\",\"dateModified\":\"2021-05-13T22:34:22+00:00\",\"description\":\"Pfizer Inc. announced that the U.S. Food and Drug Administration approved MYLOTARG\u2122 (gemtuzumab ozogamicin) for adults with newly diagnosed CD33-positive acute myeloid leukemia (AML), and adults and children 2 years and older\",\"breadcrumb\":{\"@id\":\"https:\/\/www.sfj-pharma.com\/mylortarg-received-fda-approval\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.sfj-pharma.com\/mylortarg-received-fda-approval\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.sfj-pharma.com\/mylortarg-received-fda-approval\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.sfj-pharma.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Mylortarg received FDA approval\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.sfj-pharma.com\/#website\",\"url\":\"https:\/\/www.sfj-pharma.com\/\",\"name\":\"SFJ Pharmaceuticals\",\"description\":\"Resources for Accelerated Clinical Development\",\"publisher\":{\"@id\":\"https:\/\/www.sfj-pharma.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.sfj-pharma.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.sfj-pharma.com\/#organization\",\"name\":\"SFJ Pharmaceuticals\",\"url\":\"https:\/\/www.sfj-pharma.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.sfj-pharma.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/secureservercdn.net\/198.71.233.213\/c59.835.myftpupload.com\/wp-content\/uploads\/2020\/12\/SFJ-Logo-Final-RGB.png?time=1666279552\",\"contentUrl\":\"https:\/\/secureservercdn.net\/198.71.233.213\/c59.835.myftpupload.com\/wp-content\/uploads\/2020\/12\/SFJ-Logo-Final-RGB.png?time=1666279552\",\"width\":750,\"height\":205,\"caption\":\"SFJ Pharmaceuticals\"},\"image\":{\"@id\":\"https:\/\/www.sfj-pharma.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.sfj-pharma.com\/#\/schema\/person\/049145e1c21636813c9d02a662ef41cc\",\"name\":\"khateam\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.sfj-pharma.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/9bf77b4329fc605a71e83152d4944475?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/9bf77b4329fc605a71e83152d4944475?s=96&d=mm&r=g\",\"caption\":\"khateam\"},\"sameAs\":[\"https:\/\/www.sfj-pharma.com\"],\"url\":\"https:\/\/www.sfj-pharma.com\/author\/khateam\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Mylortarg received FDA approval - SFJ Pharmaceuticals","description":"Pfizer Inc. announced that the U.S. Food and Drug Administration approved MYLOTARG\u2122 (gemtuzumab ozogamicin) for adults with newly diagnosed CD33-positive acute myeloid leukemia (AML), and adults and children 2 years and older","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.sfj-pharma.com\/mylortarg-received-fda-approval\/","og_locale":"en_US","og_type":"article","og_title":"Mylortarg received FDA approval - SFJ Pharmaceuticals","og_description":"Pfizer Inc. announced that the U.S. Food and Drug Administration approved MYLOTARG\u2122 (gemtuzumab ozogamicin) for adults with newly diagnosed CD33-positive acute myeloid leukemia (AML), and adults and children 2 years and older","og_url":"https:\/\/www.sfj-pharma.com\/mylortarg-received-fda-approval\/","og_site_name":"SFJ Pharmaceuticals","article_published_time":"2017-09-02T04:34:34+00:00","article_modified_time":"2021-05-13T22:34:22+00:00","author":"khateam","twitter_card":"summary_large_image","twitter_misc":{"Written by":"khateam","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.sfj-pharma.com\/mylortarg-received-fda-approval\/#article","isPartOf":{"@id":"https:\/\/www.sfj-pharma.com\/mylortarg-received-fda-approval\/"},"author":{"name":"khateam","@id":"https:\/\/www.sfj-pharma.com\/#\/schema\/person\/049145e1c21636813c9d02a662ef41cc"},"headline":"Mylortarg received FDA approval","datePublished":"2017-09-02T04:34:34+00:00","dateModified":"2021-05-13T22:34:22+00:00","mainEntityOfPage":{"@id":"https:\/\/www.sfj-pharma.com\/mylortarg-received-fda-approval\/"},"wordCount":202,"publisher":{"@id":"https:\/\/www.sfj-pharma.com\/#organization"},"articleSection":["News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.sfj-pharma.com\/mylortarg-received-fda-approval\/","url":"https:\/\/www.sfj-pharma.com\/mylortarg-received-fda-approval\/","name":"Mylortarg received FDA approval - SFJ Pharmaceuticals","isPartOf":{"@id":"https:\/\/www.sfj-pharma.com\/#website"},"datePublished":"2017-09-02T04:34:34+00:00","dateModified":"2021-05-13T22:34:22+00:00","description":"Pfizer Inc. announced that the U.S. Food and Drug Administration approved MYLOTARG\u2122 (gemtuzumab ozogamicin) for adults with newly diagnosed CD33-positive acute myeloid leukemia (AML), and adults and children 2 years and older","breadcrumb":{"@id":"https:\/\/www.sfj-pharma.com\/mylortarg-received-fda-approval\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.sfj-pharma.com\/mylortarg-received-fda-approval\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.sfj-pharma.com\/mylortarg-received-fda-approval\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.sfj-pharma.com\/"},{"@type":"ListItem","position":2,"name":"Mylortarg received FDA approval"}]},{"@type":"WebSite","@id":"https:\/\/www.sfj-pharma.com\/#website","url":"https:\/\/www.sfj-pharma.com\/","name":"SFJ Pharmaceuticals","description":"Resources for Accelerated Clinical Development","publisher":{"@id":"https:\/\/www.sfj-pharma.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.sfj-pharma.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.sfj-pharma.com\/#organization","name":"SFJ Pharmaceuticals","url":"https:\/\/www.sfj-pharma.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.sfj-pharma.com\/#\/schema\/logo\/image\/","url":"https:\/\/secureservercdn.net\/198.71.233.213\/c59.835.myftpupload.com\/wp-content\/uploads\/2020\/12\/SFJ-Logo-Final-RGB.png?time=1666279552","contentUrl":"https:\/\/secureservercdn.net\/198.71.233.213\/c59.835.myftpupload.com\/wp-content\/uploads\/2020\/12\/SFJ-Logo-Final-RGB.png?time=1666279552","width":750,"height":205,"caption":"SFJ Pharmaceuticals"},"image":{"@id":"https:\/\/www.sfj-pharma.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.sfj-pharma.com\/#\/schema\/person\/049145e1c21636813c9d02a662ef41cc","name":"khateam","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.sfj-pharma.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/9bf77b4329fc605a71e83152d4944475?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/9bf77b4329fc605a71e83152d4944475?s=96&d=mm&r=g","caption":"khateam"},"sameAs":["https:\/\/www.sfj-pharma.com"],"url":"https:\/\/www.sfj-pharma.com\/author\/khateam\/"}]}},"rttpg_featured_image_url":null,"rttpg_author":{"display_name":"khateam","author_link":"https:\/\/www.sfj-pharma.com\/author\/khateam\/"},"rttpg_comment":0,"rttpg_category":"<a href=\"https:\/\/www.sfj-pharma.com\/category\/news\/\" rel=\"category tag\">News<\/a>","rttpg_excerpt":"PFIZER RECEIVES FDA APPROVAL FOR MYLOTARG\u2122 (GEMTUZUMAB OZOGAMICIN) ONLY APPROVED ANTIBODY-DRUG CONJUGATE FOR NEWLY DIAGNOSED AND RELAPSED OR REFRACTORY CD33-POSITIVE ACUTE MYELOID LEUKEMIA REINTRODUCTION OF MYLOTARG SUPPORTED BY CONTINUED RESEARCH BY THE AML COMMUNITY DEMONSTRATING FAVORABLE RISK:BENEFIT PROFILE Friday, September 1, 2017 &#8211; 11:38am EDT...","_links":{"self":[{"href":"https:\/\/www.sfj-pharma.com\/wp-json\/wp\/v2\/posts\/2658"}],"collection":[{"href":"https:\/\/www.sfj-pharma.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.sfj-pharma.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.sfj-pharma.com\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.sfj-pharma.com\/wp-json\/wp\/v2\/comments?post=2658"}],"version-history":[{"count":2,"href":"https:\/\/www.sfj-pharma.com\/wp-json\/wp\/v2\/posts\/2658\/revisions"}],"predecessor-version":[{"id":8504,"href":"https:\/\/www.sfj-pharma.com\/wp-json\/wp\/v2\/posts\/2658\/revisions\/8504"}],"wp:attachment":[{"href":"https:\/\/www.sfj-pharma.com\/wp-json\/wp\/v2\/media?parent=2658"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.sfj-pharma.com\/wp-json\/wp\/v2\/categories?post=2658"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.sfj-pharma.com\/wp-json\/wp\/v2\/tags?post=2658"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}